AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- $0No open-market trades
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 4 added, 0 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Key stats
Fundamentals Sep 30- Open
- $49.17
- 52-wk high
- $60.11
- High
- $49.80
- 52-wk low
- $41.38
- Low
- $48.98
- Prev close
- $49.24
- Mkt cap
- $98.84B
- P/E
- 16.0x
- Volume
- 3.59M
- Fwd P/E
- 9.8x
- Beta
- 0.29
- Div yield
- 3.66%
- P/S
- 3.0x
- P/B
- 4.3x
- Profit margin
- +14.5%
- Op margin
- +30.9%
- ROE
- +33.4%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about GSK filings
Are insiders buying or selling GlaxoSmithKline PLC ADR (GSK) stock?
Neither. GlaxoSmithKline PLC ADR (GSK) insiders filed no open-market purchases or sales in the 90 days to Oct 1, 2026, according to SEC Form 4 filings.
Which members of Congress have traded GSK recently?
None. No member of Congress disclosed a GSK trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this GSK smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position.
What funds are doing
Buys/Adds (3)
- P7
Point72
$139.1M
bought
- DS
D.E. Shaw
$53.4M
bought
- QR
Qube Research
$26.3M
added
How top traders are positioned
No tracked top-trader positions in GSK right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 7.1% above what analysts expected.
Earnings per share
$1.27 expected
Reports Nov 4, 2026, in 34 days
Estimates as of Sep 30, 2026
EPS expected
$1.32 to $1.39
Revenue expected
8 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
Financials
What it sold, what it cost, what was left.
| USD | Jun 2025 | Dec 2025 |
|---|---|---|
| What came in | ||
| Revenue | $7.99B | $8.62B |
| Cost of what it sold | $2.17B | $2.66B |
| Gross profit | $5.82B | $5.96B |
| What it spent | ||
| Research and development | $2.02B | $2.35B |
| Sales and admin | $2.14B | $2.64B |
| Other operating costs | -$366.0M | -$534.0M |
| Total operating expenses | $3.80B | $4.46B |
| What was left | ||
| Operating profit | $2.02B | $1.51B |
| Interest on debt | $184.0M | $174.0M |
| Profit before tax | $1.89B | $950.0M |
| Tax | $241.0M | $223.0M |
| Net profit | $1.44B | $636.0M |
| EBITDA | $3.23B | $1.91B |
Technicals
Price structure
This stock is under pressure.
Trend
Under pressure
15 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace